BCL7A as a novel prognostic biomarker for glioma patients

• DOI: 10.1186/s12967-021-03003-0
• Publication Date: 2021-08-06T13:06:57Z
• Authors: Junhui Liu; Lun Gao; Baowei Ji; Rongxin Geng; Jing Chen; Xiang Tao; Qiang Cai; Zhibiao Chen
• Keywords: Brain tumor

Abstract Background Glioma is the most common primary brain tumor and represents one of aggressive lethal types human cancer. BCL7 family has been found in several cancer could be involved progression. While role glioma remained to elucidated. Methods Paraffin-embedded samples were obtained detect expression by performing glioma. Data (including normalized gene corresponding clinical data) from Gliovis, CGGA, GEO, cBioportal Oncomine used investigate genes Survival analyses calculated Kaplan–Meier methods Cox regression analysis TCGA CGGA. Gene Set Enrichment Analyses (GSEA) ontology (GO) was employed perform biological processes enrichment. Results BCL7A tissues lower compared non-tumor (NBT), exhibited a negative correlation with grades. immunohistochemical (IHC) staining public dataset validation demonstrated that BCL7B BCL7C highly expressed NBT. identified as only independently associated prognosis lower-grade (LGG) glioblastoma (GBM). GO GSEA revealed potential contribution adaptive immune response neutrophil activation microenvironment. Moreover, we had no prognostic effect on overall survival GBM patients who received IR only; however, chemotherapy (TMZ) combined high group survived longer than low (HR = 0.346, p < 0.05). Conclusion new suppressor can adopted biomarker for independent evaluate TMZ.